成都先导：拟增资参股公司先衍生物2400万元

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan Biotech, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan Biotech has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The company is advancing its drug pipeline with LDR2402, a long-acting antihypertensive drug targeting AGT, which has entered Phase II clinical trials and completed the first dosing of a subject [1] - An IND application for LDR2515, a small nucleic acid drug for obesity treatment targeting INHBE, has received implied approval from the CDE [1] Group 2: Financial and Investment Details - Chengdu XianDao plans to invest up to 15 million yuan in XianYuan Biotech, which has a registered capital of 17.24 million yuan [1] - Prior to this transaction, Chengdu XianDao held a 23.20% stake in XianYuan Biotech and intends to subscribe to an additional capital increase of 24 million yuan based on a pre-investment valuation of 450 million yuan [1] - The lead investor in this financing round is Chengdu TianShi DaoYuan GuoSheng Medical Health Venture Capital Partnership, with other investors including related parties [1]